Skip to main content
Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · Real-Time Price · USD
3.730
-0.110 (-2.86%)
At close: Nov 22, 2024, 4:00 PM
3.740
+0.010 (0.27%)
After-hours: Nov 22, 2024, 5:47 PM EST

Revance Therapeutics Revenue

Revance Therapeutics had revenue of $59.88M in the quarter ending September 30, 2024, with 10.66% growth. This brings the company's revenue in the last twelve months to $256.95M, up 25.82% year-over-year. In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth.

Revenue (ttm)
$256.95M
Revenue Growth
+25.82%
P/S Ratio
1.40
Revenue / Employee
$430,394
Employees
597
Market Cap
391.29M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023234.04M101.48M76.55%
Dec 31, 2022132.57M54.77M70.40%
Dec 31, 202177.80M62.47M407.65%
Dec 31, 202015.33M14.91M3,610.65%
Dec 31, 2019413.00K-3.32M-88.92%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
DocGo 694.97M
Canopy Growth 207.63M
AirSculpt Technologies 188.78M
Akebia Therapeutics 169.88M
Aquestive Therapeutics 58.90M
Sangamo Therapeutics 52.29M
Tango Therapeutics 43.38M
Revenue Rankings

RVNC News

More News